Cancer Stem Cell Hierarchy in Glioblastoma Multiforme

Frontiers in Surgery

Volumn 3, Issue , 2016, Pages

  Bradshaw, Amy ^a   Wickremsekera, Agadha ^a,b   Tan, Swee T ^a   Peng, Lifeng ^c   Davis, Paul F ^a   Itinteang, Tinte ^a  

^a GILLIES MCINDOE RESEARCH INSTITUTE   (New Zealand)

^b WELLINGTON HOSPITAL   (New Zealand)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

cancer; cancer stem cell; glioblastoma multiforme; hierarchy; markers

Indexed keywords

EID: 84986889650     PISSN: None     EISSN: 2296875X     Source Type: Journal    
DOI: 10.3389/fsurg.2016.00021     Document Type: Review

References (244)

1. Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer (2007) 96(8):1293–301.10.1038/sj.bjc.660380217375044
2. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A (2000) 97(12):6242–4.10.1073/pnas.97.12.6242
3. Lonser RR, Walbridge S, Vortmeyer AO, Pack SD, Nguyen TT, Gogate N, et al. Induction of glioblastoma multiforme in nonhuman primates after therapeutic doses of fractionated whole-brain radiation therapy. J Neurosurg (2002) 97(6):1378–89.10.3171/jns.2002.97.6.137812507137
4. Surawicz TS, Davis F, Freels S, Laws ER, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol (1998) 40(2):151–60.10.1023/A:10060916085869892097
5. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res (2009) 7(7):989–99.10.1158/1541-7786.MCR-09-003019609002
6. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res (2002) 62(1):200–7.11782378
7. Seymour T, Nowak A, Kakulas F. Targeting aggressive cancer stem cells in glioblastoma. Front Oncol (2015) 5:159.10.3389/fonc.2015.0015926258069
8. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10(5):459–66.10.1016/S1470-2045(09)70025-7
9. Milano MT, Okunieff P, Donatello RS, Mohile NA, Sul J, Walter KA, et al. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys (2010) 78(4):1147–55.10.1016/j.ijrobp.2009.09.01820207495
10. Outlines P. CNS Tumor Astrocytic Tumors Glioblastoma Multiforme. (2013). Available from: http://www.pathologyoutlines.com/topic/cnstumorglioblastoma.html
11. Rong Y, Durden DL, Van Meir EG, Brat DJ. ‘Pseudopalisading’ necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol (2006) 65(6):529–39.10.1097/00005072-200606000-00001
12. Moore K, Kim L. Primary brain tumours: characteristics, practical diagnostic and treatment approaches. In: Ray SK, editor. Glioblastoma: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies. New York: Springer Science + Business Media, LLC (2009). p. 43–75.
13. Liu Q, Liu Y, Li W, Wang X, Sawaya R, Lang FF, et al. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathol (2015) 130(4):587–97.10.1007/s00401-015-1470-8
14. Kim DH, Mohapatka G, Bollen A, Waldman FM, Feuerstein BG. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer (1995) 60(6):812–9.10.1002/ijc.29106006157896451
15. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 17(1):98–110.10.1016/j.ccr.2009.12.02020129251
16. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res (2008) 68(11):4018–21.10.1158/0008-5472.CAN-07-633418519656
17. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell (2009) 138(5):822–9.10.1016/j.cell.2009.08.01719737509
18. Schneider M, Ströbele S, Nonnenmacher L, Siegelin MD, Tepper M, Stroh S, et al. A paired comparison between glioblastoma “stem cells” and differentiated cells. Int J Cancer (2016) 138(7):1709–18.10.1002/ijc.29908
19. Salk JJ, Fox EJ, Loeb LA. Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol (2010) 5:51.10.1146/annurev-pathol-121808-10211319743960
20. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 63(18):5821–8.14522905
21. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature (2004) 432(7015):396–401.10.1038/nature0312815549107
22. Lathia JD, Heddleston JM, Venere M, Rich JN. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell (2011) 8(5):482–5.10.1016/j.stem.2011.04.01321549324
23. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, et al. Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest (2007) 117(5):1305.10.1172/JCI30740
24. Gage FH. Mammalian neural stem cells. Science (2000) 287(5457):1433–8.10.1126/science.287.5457.143310688783
25. Billing AM, Dib SS, Hamidane HB, Goswami N, Al-mismar R, Cotton R, et al., editors. Comprehensive characterization of the differentiation of human embryonic stem cells into mesenchymal stem cells. Qatar Foundation Annual Research Conference. Doha, Qatar (2014).
26. Rafii S, Kloss CC, Butler JM, Ginsberg M, Gars E, Lis R, et al. Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition. Blood (2013) 121(5):770–80.10.1182/blood-2012-07-44420823169780
27. Doulatov S, Vo LT, Chou SS, Kim PG, Arora N, Li H, et al. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell (2013) 13(4):459–70.10.1016/j.stem.2013.09.00224094326
28. Dietrich J, Imitola J, Kesari S. Mechanisms of disease: the role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol (2008) 5(7):393–404.10.1038/ncponc113218521117
29. Zhao X, Das AV, Thoreson WB, James J, Wattnem TE, Rodriguez-Sierra J, et al. Adult corneal limbal epithelium: a model for studying neural potential of non-neural stem cells/progenitors. Dev Biol (2002) 250(2):317–31.10.1006/dbio.2002.079312376106
30. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res (2008) 14(1):123–9.10.1158/1078-0432.CCR-07-093218172261
31. Suga H, Matsumoto D, Eto H, Inoue K, Aoi N, Kato H, et al. Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. Stem Cells Dev (2009) 18(8):1201–10.10.1089/scd.2009.000319226222
32. Horky LL, Galimi F, Gage FH, Horner PJ. Fate of endogenous stem/progenitor cells following spinal cord injury. J Comp Neurol (2006) 498(4):525–38.10.1002/cne.2106516874803
33. Tanaka M, Itoh T, Tanimizu N, Miyajima A. Liver stem/progenitor cells: their characteristics and regulatory mechanisms. J Biochem (2011) 149(3):231–9.10.1093/jb/mvr00121217146
34. Vankelecom H. Pituitary stem/progenitor cells: embryonic players in the adult gland? Eur J Neurosci (2010) 32(12):2063–81.10.1111/j.1460-9568.2010.07523.x21143661
35. Seaberg RM, van der Kooy D. Stem and progenitor cells: the premature desertion of rigorous definitions. Trends Neurosci (2003) 26(3):125–31.10.1016/S0166-2236(03)00031-6
36. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 367(6464):645–8.10.1038/367645a0
37. Rajaraman R. The origin of tumor cell heterogeneity. IUP J Biotechnol (2010) 4(4):7–43.
38. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest (2008) 88(5):459–63.10.1038/labinvest.2008.14
39. Kim EJ, Khan GN, Griffith K, Greenson J, Takebe N, Zalupski M, et al. Abstract A40: Cancer stem cells (CSC) and inhibition of hedgehog (Hh) pathway signaling in advanced pancreatic cancer: GDC-0449 in combination with gemcitabine (Gem). Cancer Res (2012) 72(Suppl 14):A40.10.1158/1538-7445.panca2012-a40
40. Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K. Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis (2015) 2:152–63.10.1016/j.gendis.2015.02.00126137500
41. Foreman KE, Rizzo P, Osipo C, Miele L. The cancer stem cell hypothesis. In: Bagley RG, Teicher BA, editors. Stem Cells and Cancer. New York: Springer Science + Business Media, LLC (2009). p. 3–14.
42. Tamura K, Aoyagi M, Ando N, Ogishima T, Wakimoto H, Yamamoto M, et al. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy: laboratory investigation. J Neurosurg (2013) 119(5):1145–55.10.3171/2013.7.JNS122417
43. Diehn M, Cho RW, Clarke MF. Therapeutic implications of the cancer stem cell hypothesis. Semin Radiat Oncol (2009) 19(2):78–86.10.1016/j.semradonc.2008.11.002
44. Barabé F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science (2007) 316(5824):600–4.10.1126/science.113985117463288
45. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 117(9):2562–9.10.1172/JCI3089017710227
46. Morokoff A, Ng W, Gogos A, Kaye A. Molecular subtypes, stem cells and heterogeneity: implications for personalised therapy in glioma. J Clin Neurosci (2015) 22:1219–26.10.1016/j.jocn.2015.02.00825957782
47. Jhanwar-Uniyal M, Labagnara M, Friedman M, Kwasnicki A, Murali R. Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers (2015) 7(2):538–55.10.3390/cancers702053825815458
48. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell (2013) 24(3):331–46.10.1016/j.ccr.2013.08.00123993863
49. Mao P, Joshi K, Li J, Kim S-H, Li P, Santana-Santos L, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A (2013) 110(21):8644–9.10.1073/pnas.122147811023650391
50. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 15(6):501–13.10.1016/j.ccr.2009.03.01819477429
51. Ricci-Vitiani L, Pallini R, Larocca LM, Lombardi DG, Signore M, Pierconti F, et al. Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ (2008) 15(9):1491–8.10.1038/cdd.2008.7218497759
52. Nakano I. Stem cell signature in glioblastoma: therapeutic development for a moving target. J Neurosurg (2015) 122(2):324–30.10.3171/2014.9.JNS13225325397368
53. Stieber D, Golebiewska A, Evers L, Lenkiewicz E, Brons NH, Nicot N, et al. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol (2014) 127(2):203–19.10.1007/s00401-013-1196-424154962
54. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia (2012) 60(3):502–14.10.1002/glia.2126422379614
55. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature (1981) 292(5819):154–6.10.1038/292154a0
56. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science (1998) 282(5391):1145–7.10.1126/science.282.5391.11459804556
57. Zhao W, Ji X, Zhang F, Li L, Ma L. Embryonic stem cell markers. Molecules (2012) 17(6):6196–236.10.3390/molecules1706619622634835
58. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun (2009) 383(2):157–62.10.1016/j.bbrc.2009.02.15619268426
59. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 126(4):663–76.10.1016/j.cell.2006.07.02416904174
60. Kim D, Kim C-H, Moon J-I, Chung Y-G, Chang M-Y, Han B-S, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell (2009) 4(6):472.10.1016/j.stem.2009.05.005
61. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell (2014) 14(3):275–91.10.1016/j.stem.2014.02.006
62. Zhao X, Sun X, Li XL. Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. Asian Pac J Cancer Prev (2012) 13(6):2873–7.10.7314/APJCP.2012.13.6.287322938476
63. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2008) 15(3):504–14.10.1038/sj.cdd.440228318049477
64. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 100(7):3983–8.10.1073/pnas.053029110012629218
65. Prince M, Sivanandan R, Kaczorowski A, Wolf G, Kaplan M, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A (2007) 104(3):973–8.10.1073/pnas.061011710417210912
66. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol (2008) 26(17):2862–70.10.1200/JCO.2007.15.147218539965
67. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 25(12):1696–708.10.1038/sj.onc.1209327
68. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 1(3):313–23.10.1016/j.stem.2007.06.00218371365
69. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res (2007) 67(3):1030–7.10.1158/0008-5472.CAN-06-203017283135
70. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2007) 445(7123):106–10.10.1038/nature05372
71. Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R. Colon cancer stem cells. J Mol Med (2009) 87(11):1097–104.10.1007/s00109-009-0518-419727638
72. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia (2002) 39(3):193–206.10.1002/glia.1009412203386
73. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 23(58):9392–400.10.1038/sj.onc.1208311
74. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 67(9):4010–5.10.1158/0008-5472.CAN-06-4180
75. Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL, et al. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells (2009) 27(8):1722–33.10.1002/stem.9819544433
76. Piccirillo SG, Binda E, Fiocco R, Vescovi AL, Shah K. Brain cancer stem cells. J Mol Med (2009) 87(11):1087–95.10.1007/s00109-009-0535-319784875
77. Field M, Alvarez A, Bushnev S, Sugaya K. Embryonic stem cell markers distinguishing cancer stem cells from normal human neuronal stem cell populations in malignant glioma patients. Clin Neurosurg (2010) 57:151–9.23801830
78. Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell (2009) 4(1):16–9.10.1016/j.stem.2008.11.014
79. Olmez I, Shen W, McDonald H, Ozpolat B. Dedifferentiation of patient-­derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth. J Cell Mol Med (2015) 19:1262–72.10.1111/jcmm.1247925787115
80. Zhang L, Yan Y, Jiang Y, Cui Y, Zou Y, Qian J, et al. The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome. J Neurooncol (2015) 121(2):261–8.10.1007/s11060-014-1646-425359397
81. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene (2002) 21(55):8404–13.10.1038/sj.onc.120604712466961
82. Shin S, Sun Y, Liu Y, Khaner H, Svant S, Cai J, et al. Whole genome analysis of human neural stem cells derived from embryonic stem cells and stem and progenitor cells isolated from fetal tissue. Stem Cells (2007) 25(5):1298–306.10.1634/stemcells.2006-066017272497
83. Ratajczak MZ, Kucia M, Majka M, Reca R, Ratajczak J. Heterogeneous populations of bone marrow stem cells – are we spotting on the same cells from the different angles? Folia Histochem Cytobiol (2004) 42(3):139–46.15493574
84. Cai C, Grabel L. Directing the differentiation of embryonic stem cells to neural stem cells. Dev Dyn (2007) 236(12):3255–66.10.1002/dvdy.2130617823944
85. Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A (1999) 96(6):3120–5.10.1073/pnas.96.6.312010077647
86. Bartis D, Pongrácz J. Three Dimensional Tissue Cultures and Tissue Engineering. Hungary: University of Pécs (2011). Retrieved from Digitalis Tankonyvtar.
87. Passegué E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med (2005) 202(11):1599–611.10.1084/jem.2005096716330818
88. Perez-Losada J, Balmain A. Stem-cell hierarchy in skin cancer. Nat Rev Cancer (2003) 3(6):434–43.10.1038/nrc109512778133
89. Villadsen R, Fridriksdottir AJ, Rønnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA, et al. Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol (2007) 177(1):87–101.10.1083/jcb.20061111417420292
90. Zhang J, Tam W-L, Tong GQ, Wu Q, Chan H-Y, Soh B-S, et al. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol (2006) 8(10):1114–23.10.1038/ncb148116980957
91. Yang J, Chai L, Fowles TC, Alipio Z, Xu D, Fink LM, et al. Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in ­murine-embryonic stem cells. Proc Natl Acad Sci U S A (2008) 105(50):19756–61.10.1073/pnas.080932110519060217
92. Elling U, Klasen C, Eisenberger T, Anlag K, Treier M. Murine inner cell mass-derived lineages depend on Sall4 function. Proc Natl Acad Sci U S A (2006) 103(44):16319–24.10.1073/pnas.060788410317060609
93. Lim CY, Tam W-L, Zhang J, Ang HS, Jia H, Lipovich L, et al. Sall4 regulates distinct transcription circuitries in different blastocyst-derived stem cell lineages. Cell Stem Cell (2008) 3(5):543–54.10.1016/j.stem.2008.08.00418804426
94. Wu Q, Chen X, Zhang J, Loh Y-H, Low T-Y, Zhang W, et al. Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. J Biol Chem (2006) 281(34):24090–4.10.1074/jbc.C60012220016840789
95. Kobayashi D, Kuribayshi K, Tanaka M, Watanabe N. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int J Oncol (2011) 38(4):933–9.10.3892/ijo.2011.92921274508
96. Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N. Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep (2011) 26(4):965–70.10.3892/or.2011.137421725617
97. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology (2013) 57(4):1469–83.10.1002/hep.2615923175232
98. He J, Zhang W, Zhou Q, Zhao T, Song Y, Chai L, et al. Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol (2013) 45(9):1962–73.10.1016/j.biocel.2013.06.00823811124
99. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 16(3):800–13.10.1158/1078-0432.CCR-09-273020103663
100. Jha P, Patric IRP, Shukla S, Pathak P, Pal J, Sharma V, et al. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Neuro Oncol (2014) 16(12):1607–17.10.1093/neuonc/nou11324997139
101. Mei K, Liu A, Allan RW, Wang P, Lane Z, Abel TW, et al. Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol (2009) 22(12):1628–36.10.1038/modpathol.2009.14819820689
102. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 122(6):947–56.10.1016/j.cell.2005.08.020
103. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell (1998) 95(3):379–91.10.1016/S0092-8674(00)81769-99814708
104. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, et al. Expression profile of ­embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology (2011) 59(4):763–75.10.1111/j.1365-2559.2011.03993.x22014056
105. Talsma CE, Flack CG, Zhu T, He X, Soules M, Heth JA, et al., editors. Oct4 regulates GBM neurosphere growth and its expression is associated with poor survival in GBM patients. Neuro-Oncology. Cary, NC: Oxford University Press Inc. Journals Dept. (2011). p. 147–157.
106. Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y, et al. Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia (2009) 57(7):724–33.10.1002/glia.2080018985733
107. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res (1999) 27(6):1409–20.10.1093/nar/27.6.140910037800
108. Dong C, Wilhelm D, Koopman P. Sox genes and cancer. Cytogenet Genome Res (2004) 105(2–4):442–7.10.1159/000078217
109. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol (2009) 16(12):3488–98.10.1245/s10434-009-0617-z19657699
110. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem (2008) 283(26):17969–78.10.1074/jbc.M80291720018456656
111. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 44(10):1111–6.10.1038/ng.240522941189
112. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc (2007) 2(12):3081–9.10.1038/nprot.2007.41818079707
113. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol (2008) 26(11):1269–75.10.1038/nbt.150218849973
114. Gangemi RMR, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells (2009) 27(1):40–8.10.1634/stemcells.2008-049318948646
115. Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron (2003) 39(5):749–65.10.1016/S0896-6273(03)00497-512948443
116. Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev (2008) 22(23):3320–34.10.1101/gad.1726608
117. Fauquier T, Rizzoti K, Dattani M, Lovell-Badge R, Robinson IC. SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland. Proc Natl Acad Sci U S A (2008) 105(8):2907–12.10.1073/pnas.070788610518287078
118. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A (2011) 108(24):9951–6.10.1073/pnas.101691210821628563
119. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature (2012) 482(7384):216–20.10.1038/nature10821
120. Ellis P, Fagan BM, Magness ST, Hutton S, Taranova O, Hayashi S, et al. SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci (2004) 26(2–4):148–65.10.1159/00008213415711057
121. Takeda K, Akira S. Multi-functional roles of Stat3 revealed by conditional gene targeting. Arch Immunol Ther Exp (2001) 49(4):279–83.11726030
122. Raz R, Lee C-K, Cannizzaro LA, d’Eustachio P, Levy DE. Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci U S A (1999) 96(6):2846–51.10.1073/pnas.96.6.284610077599
123. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivitol target for individualized treatment of cancer. Cell Cycle (2005) 4(9):1131–3.10.4161/cc.4.9.1985
124. Levy DE, Lee CK. What does Stat3 do? J Clin Invest (2002) 109(9):1143–8.10.1172/JCI0215650
125. Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF ­signalling pathways maintains pluripotency of mouse ES cells. Nature (2009) 460(7251):118–22.10.1038/nature0811319571885
126. Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev (1998) 12(13):2048–60.10.1101/gad.12.13.20489649508
127. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 94(8):3801–4.10.1073/pnas.94.8.38019108058
128. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 9(11):798–809.10.1038/nrc273419851315
129. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A (2003) 100(7):4138–43.10.1073/pnas.053476410012640143
130. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 12(1):11–9.10.1158/1078-0432.CCR-04-175216397018
131. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of STAT3 in human prostate tumors and cell lines direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 62(22):6659–66.12438264
132. Couto JP, Daly L, Almeida A, Knauf JA, Fagin JA, Sobrinho-Simões M, et al. STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A (2012) 109(35):E2361–70.10.1073/pnas.120123210922891351
133. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev (2005) 24(2):315–27.10.1007/s10555-005-1580-115986140
134. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells (2009) 27(10):2383–92.10.1002/stem.18519658181
135. de la Iglesia N, Konopka G, Lim K-L, Nutt CL, Bromberg JF, Frank DA, et al. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci (2008) 28(23):5870–8.10.1523/JNEUROSCI.5385-07.200818524891
136. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008) 22(4):449–62.10.1101/gad.160650818258752
137. Senft C, Priester M, Polacin M, Schröder K, Seifert V, Kögel D, et al. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol (2011) 101(3):393–403.10.1007/s11060-010-0273-y20589525
138. Yang YP, Chang YL, Huang PI, Chiou GY, Tseng LM, Chiou SH, et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol (2012) 227(3):976–93.10.1002/jcp.2280621503893
139. Gariboldi MB, Ravizza R, Monti E. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol (2010) 80(4):455–62.10.1016/j.bcp.2010.05.01120488164
140. Villalva C, Martin-Lannerée S, Cortes U, Dkhissi F, Wager M, Le Corf A, et al. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int J Cancer (2011) 128(4):826–38.10.1002/ijc.2541620473906
141. Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer (2009) 100(1):106–12.10.1038/sj.bjc.660479319127268
142. Cao F, Hata R, Zhu P, Nakashiro K-i, Sakanaka M. Conditional deletion of Stat3 promotes neurogenesis and inhibits astrogliogenesis in neural stem cells. Biochem Biophys Res Commun (2010) 394(3):843–7.10.1016/j.bbrc.2010.03.09220303333
143. Chiou S-H, Wang M-L, Chou Y-T, Chen C-J, Hong C-F, Hsieh W-J, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res (2010) 70(24):10433–44.10.1158/­0008-5472.CAN-10-263821159654
144. Chiou S-H, Yu C-C, Huang C-Y, Lin S-C, Liu C-J, Tsai T-H, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res (2008) 14(13):4085–95.10.1158/1078-0432.CCR-07-440418593985
145. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem (2008) 283(25):17635–51.10.1074/jbc.M80010920018441325
146. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase Cϵ promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem (2009) 284(39):26533–46.10.1074/jbc.M109.02746612438264
147. Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene (2011) 30(36):3833–45.10.1038/onc.2011.11421499299
148. Clement V, Sanchez P, De Tribolet N, Radovanovic I, i Altaba AR. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol (2007) 17(2):165–72.10.1016/j.cub.2007.01.02417196391
149. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 8(20):3274–84.10.4161/cc.8.20.970119770585
150. Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G, et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J (2010) 29(15):2646–58.10.1038/emboj.2010.13120581804
151. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, i Altaba AR. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J (2010) 29(15):2659–74.10.1038/emboj.2010.13720581802
152. Niu CS, Yang Y, Cheng C-D. MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. Int J Oncol (2013) 42(5):1533–40.10.3892/ijo.2013.184423467648
153. Loh Y-H, Wu Q, Chew J-L, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet (2006) 38(4):431–40.10.1038/ng176016518401
154. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell (2003) 113(5):631–42.10.1016/S0092-8674(03)00393-312787504
155. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 318(5858):1917–20.10.1126/science.115152618029452
156. Möröy T, Fisher P, Guidos C, Ma A, Zimmerman K, Tesfaye A, et al. IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis. EMBO J (1990) 9(11):3659.2120050
157. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, et al. Function of the c-Myc oncogenic transcription factor. Exp Cell Res (1999) 253(1):63–77.10.1006/excr.1999.468610579912
158. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A (2000) 97(7):3260–5.10.1073/pnas.97.7.326010737792
159. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 103(48):18261–6.10.1073/pnas.060610810317114293
160. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ (1997) 8(10):1039–48.
161. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev (1993) 7(4):671–82.10.1101/gad.7.4.6718458579
162. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1983) 306:194–6.10.1038/306194a06646201
163. Lewis BC, Klimstra DS, Varmus HE. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. Genes Dev (2003) 17(24):3127–38.10.1101/gad.114040314681205
164. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 21(9):1156–67.10.1038/modpathol.2008.11118567993
165. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res (1987) 47(24 Pt 1):6517–21.3677090
166. Chen C-R, Kang Y, Massagué J. Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor β growth arrest program. Proc Natl Acad Sci U S A (2001) 98(3):992–9.10.1073/pnas.98.3.992
167. Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res (1990) 50(8):2347–50.2180567
168. Zheng H, Ying H, Yan H, Kimmelman A, Hiller D, Chen A-J, et al. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harbor Symposia on Quantitative Biology. Cold Spring Harbor Laboratory Press (2008).
169. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2008) 26(1):101–6.10.1038/nbt137418059259
170. Broers JL, Viallet J, Jensen SM, Pass H, Travis WD, Minna JD, et al. Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol (1993) 9:33–43.10.1165/ajrcmb/9.1.338393325
171. Rao G, Pedone CA, Coffin CM, Holland EC, Fults DW. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia (2003) 5(3):198–204.10.1016/S1476-5586(03)80052-012869303
172. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 3(11):e3769.10.1371/journal.pone.000376919020659
173. Herms JW, von Loewenich FD, Behnke J, Markakis E, Kretzschmar HA. c-Myc oncogene family expression in glioblastoma and survival. Surg Neurol (1999) 51(5):536–42.10.1016/S0090-3019(98)00028-710321885
174. Dang DT, Pevsner J, Yang VW. The biology of the mammalian Krüppel-like family of transcription factors. Int J Biochem Cell Biol (2000) 32(11):1103–21.10.1016/S1357-2725(00)00059-511137451
175. Bieker JJ. Krüppel-like factors: three fingers in many pies. J Biol Chem (2001) 276(37):34355–8.10.1074/jbc.R100043200
176. Ivey KN, Muth A, Arnold J, King FW, Yeh R-F, Fish JE, et al. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell (2008) 2(3):219–29.10.1016/j.stem.2008.01.01618371447
177. Nakatake Y, Fukui N, Iwamatsu Y, Masui S, Takahashi K, Yagi R, et al. Klf4 cooperates with Oct3/4 and Sox2 to activate the Lefty1 core promoter in embryonic stem cells. Mol Cell Biol (2006) 26(20):7772–82.10.1128/MCB.00468-0616954384
178. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene (2011) 30(18):2161–72.10.1038/onc.2010.59121242971
179. Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKie-Bell P, Grizzle W, et al. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ (1999) 10(6):423–34.10392904
180. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, et al. Induction of KLF4 in basal keratinocytes blocks the proliferation–differentiation switch and initiates squamous epithelial dysplasia. Oncogene (2005) 24(9):1491–500.10.1038/sj.onc.1208307
181. Wei D, Kanai M, Huang S, Xie K. Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis (2005) 27(1):23–31.10.1093/carcin/bgi243
182. Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, et al. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res (2010) 70(24):10182–91.10.1158/0008-5472.CAN-10-241421159640
183. Chen H-Y, Lin Y-M, Chung H-C, Lang Y-D, Lin C-J, Huang J, et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res (2012) 72(14):3631–41.10.1158/0008-5472.CAN-12-066722593189
184. Akaogi K, Nakajima Y, Ito I, Kawasaki S, Oie S, Murayama A, et al. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERα. Oncogene (2009) 28(32):2894–902.10.1038/onc.2009.151
185. Zhou Y, Hofstetter WL, He Y, Hu W, Pataer A, Wang L, et al. KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther (2010) 9(7):507–13.10.4161/cbt.9.7.1110620215880
186. Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer (2006) 6(1):11–23.10.1038/nrc178016372018
187. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene (2004) 23(2):395–402.10.1038/sj.onc.120706714724568
188. Yoon HS, Chen X, Yang VW. Krüppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem (2003) 278(4):2101–5.10.1074/jbc.M211027200
189. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 7(11):1074–82.10.1038/ncb131416244670
190. Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z, et al. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4. Cancer Lett (2014) 355(1):85–95.10.1016/j.canlet.2014.09.01225218589
191. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2007) 20(1):102–7.10.1038/modpathol.380072017143262
192. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res (2007) 67(10):4807–15.10.1158/0008-5472.CAN-06-460817510410
193. Su H-T, Weng C-C, Hsiao P-J, Chen L-H, Kuo T-L, Chen Y-W, et al. Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer. Mol Cancer Res (2013) 11(7):768–79.10.1158/1541-7786.MCR-12-051123552743
194. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 444(7120):756–60.10.1038/nature0523617051156
195. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 5(1):67.10.1186/1476-4598-5-6717140455
196. Hatanpaa KJ, Hu T, Vemireddy V, Foong C, Raisanen JM, Oliver D, et al. High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II–III astrocytomas and oligoastrocytomas. J Neurooncol (2014) 117(1):183–9.10.1007/s11060-014-1376-7
197. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res (2008) 27(1):1–7.10.1186/1756-9966-27-8519108713
198. Staberg M, Villingshøj M, Stockhausen M, Poulsen H. P01.20epigenetic treatment and induction of differentiation in glioblastoma multiforme neurosphere cells leads to downregulation of EGFR, EGFRvIII and nestin together with reduced colony formation in vitro. Neurooncology (2014) 16(Suppl 2):ii31–ii.10.1093/neuonc/nou174.113
199. Frederiksen K, McKay R. Proliferation and differentiation of rat ­neuroepithelial precursor cells in vivo. J Neurosci (1988) 8(4):1144–51.3357014
200. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell (1990) 60(4):585–95.10.1016/0092-8674(90)90662-X1689217
201. Dahlstrand J, Lardelli M, Lendahl U. Nestin mRNA expression correlates with the central nervous system progenitor cell state in many, but not all, regions of developing central nervous system. Dev Brain Res (1995) 84(1):109–29.10.1016/0165-3806(94)00162-S7720210
202. Suzuki S, Namiki J, Shibata S, Mastuzaki Y, Okano H. The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. J Histochem Cytochem (2010) 58(8):721–30.10.1369/jhc.2010.95560920421592
203. Gomes FC, Paulin D, Moura Neto V. Glial fibrillary acidic protein (GFAP): modulation by growth factors and its implication in astrocyte differentiation. Braz J Med Biol Res (1999) 32(5):619–31.10.1590/S0100-879X199900050001610412574
204. Middeldorp J, Hol E. GFAP in health and disease. Prog Neurobiol (2011) 93(3):421–43.10.1016/j.pneurobio.2011.01.00521219963
205. Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell (1999) 97(6):703–16.10.1016/S0092-8674(00)80783-710380923
206. Imura T, Kornblum HI, Sofroniew MV. The predominant neural stem cell isolated from postnatal and adult forebrain but not early embryonic forebrain expresses GFAP. J Neurosci (2003) 23(7):2824–32.12684469
207. Glass R, Synowitz M, Kronenberg G, Walzlein J-H, Markovic DS, Wang L-P, et al. Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci (2005) 25(10):2637–46.10.1523/JNEUROSCI.5118-04.200515758174
208. Jung C, Foerch C, Schänzer A, Heck A, Plate K, Seifert V, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain (2007) 130(12):3336–41.10.1093/brain/awm26317998256
209. Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med (2014) 6(247):ra101–247.10.1126/scitranslmed.300909525080476
210. Tichy J, Spechtmeyer S, Mittelbronn M, Hattingen E, Rieger J, Senft C, et al. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neurooncol (2015) 126(2):361–9.10.1007/s11060-015-1978-8
211. Hamilton JD, Rapp M, Schneiderhan TM, Sabel M, Hayman A, Scherer A, et al. Glioblastoma multiforme metastasis outside the CNS: three case reports and possible mechanisms of escape. J Clin Oncol (2014) 32(22):e80–4.10.1200/JCO.2013.48.7546
212. Hamaya K, Doi K, Tanaka T, Nishimoto A. The determination of glial fibrillary acidic protein for the diagnosis and histogenetic study of central nervous system tumors: a study of 152 cases. Acta Med Okayama (1985) 39(6):453–62.4091041
213. Abaza MSI, Narayan RK, Atassi M. In vitro efficacy of anti-glial fibrillary acidic protein monoclonal antibodies against human malignant glioma cell lines. Cancer Sci (1997) 88(11):1094–9.9439685
214. Jung C, Unterberg A, Hartmann C. Diagnostic markers for glioblastoma. Histol Histopathol (2011) 26(10):1327–41.21870336
215. Fargeas CA, Corbeil D, Huttner WB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells (2003) 21(4):506–8.10.1634/stemcells.21-4-506
216. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood (1997) 90(12):5002–12.9389720
217. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 118(6):2111.10.1172/JCI3440118497886
218. Yan X, Ma L, Yi D, Yoon J-g, Diercks A, Foltz G, et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A (2011) 108(4):1591–6.10.1073/pnas.101869610821220328
219. Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer (2008) 122(4):761–8.10.1002/ijc.2313017955491
220. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell (1989) 56(6):1057–62.10.1016/0092-8674(89)90638-72466575
221. Lesley J, English N, Perschl A, Gregoroff J, Hyman R. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J Exp Med (1995) 182(2):431–7.10.1084/jem.182.2.4317543138
222. Sneath R, Mangham D. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol (1998) 51(4):191.10.1136/mp.51.4.1919893744
223. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci (2002) 39(6):527–79.10.1080/10408360290795574
224. Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res (2008) 14(21):6751–60.10.1158/1078-0432.CCR-08-103418980968
225. Wielenga VJ, Heider K-H, Johan G, Offerhaus A, Adolf GR, van den Berg FM, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res (1993) 53(20):4754–6.7691404
226. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 17(2):211–5.10.1038/nm.228421240262
227. Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K, et al. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate (2001) 49(2):110–5.10.1002/pros.112411582589
228. Kaufmann M, von Minckwitz G, Heider K, Ponta H, Herrlich P, Sinn H. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet (1995) 345(8950):615–9.10.1016/S0140-6736(95)90521-97534855
229. Götte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res (2006) 66(21):10233–7.10.1158/0008-5472.CAN-06-146417079438
230. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med (1997) 186(12):1985–96.10.1084/jem.186.12.19859396767
231. Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck (2012) 34(1):42–9.10.1002/hed.2169921322081
232. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem (2001) 276(24):20809–12.10.1074/jbc.C10014020011320076
233. Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat (2008) 11(3):110–21.10.1016/j.drup.2008.04.00218490190
234. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol (1999) 17(11):3494–502.10550147
235. Saegusa M, Machida D, Hashimura M, Okayasu I. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression. J Pathol (1999) 189(3):326–37.10.1002/(SICI)1096-9896(199911)189:3<326::AID-PATH425>3.0.CO;2-6
236. Pirinen R, Hirvikoski P, Böhm J, Kellokoski J, Moisio K, Virén M, et al. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol (2000) 31(9):1088–95.10.1053/hupa.2000.1627711014576
237. Maula S, Huuhtanen R, Blomqvist C, Wiklund T, Laurila P, Ristamäki R. The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas. Br J Cancer (2001) 84(2):244.10.1054/bjoc.2000.159011161384
238. Li H, Hamou M-F, de Tribolet N, Jaufeerally R, Hofmann M, Diserens A-C, et al. Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res (1993) 53(22):5345–9.7693337
239. Eibl RH, Pietsch T, Moll J, Skroch-Angel P, Heider K-H, von Ammon K, et al. Expression of variant CD44 epitopes in human astrocytic brain tumors. J Neurooncol (1995) 26(3):165–70.10.1007/BF010526198750182
240. Kaaijk P, Troost D, Morsink F, Keehnen RM, Leenstra S, Bosch DA, et al. Expression of CD44 splice variants in human primary brain tumors. J Neurooncol (1995) 26(3):185–90.10.1007/BF010526218750184
241. Breyer R, Hussein S, Radu DL, Pütz K-M, Gunia S, Hecker H, et al. Disruption of intracerebral progression of rat C6 glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J Neurosurg (2000) 92(1):140–9.10.3171/jns.2000.92.1.0140
242. Asher R, Bignami A. Hyaluronate binding and CD44 expression in human glioblastoma cells and astrocytes. Exp Cell Res (1992) 203(1):80–90.10.1016/0014-4827(92)90042-71426053
243. Naruse M, Shibasaki K, Yokoyama S, Kurachi M, Ishizaki Y. Dynamic changes of CD44 expression from progenitors to subpopulations of astrocytes and neurons in developing cerebellum. PLoS One (2013) 8(1):e53109.10.1371/journal.pone.005310923308146
244. Yokota T, Oritani K, Butz S, Kokame K, Kincade PW, Miyata T, et al. The endothelial antigen ESAM marks primitive hematopoietic progenitors throughout life in mice. Blood (2009) 113(13):2914–23.10.1182/blood-2008-07-16710619096010